Journals / Balkan Medical Journal / 2015 / Cilt: 32 - Sayı: 2

Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals

Pages
147–155
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This resultindicates that the TT genotype may be more effective inthe progression of HCV infection than other genotypes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Host genetic factors can affect the prog- ress of hepatitis-C virus (HCV) infection.
📊
Key Findings & Data:Interleukin- 28B (IL28B) single nucleotide polymorphisms mayplay an important role in the clearance of HCV sponta- neously or with treatment.
💡
Conclusion & Impact:This resultindicates that the TT genotype may be more effective inthe progression of HCV infection than other genotypes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Host genetic factors can affect the prog- ress of hepatitis-C virus (HCV) infection. Interleukin- 28B (IL28B) single nucleotide polymorphisms mayplay an important role in the clearance of HCV sponta- neously or with treatment. Aims: The aim of our study was to evaluate the rateof IL28B genotypes in patients with Chronic Hep- atitis-C (CHC) and healthy control subjects and toexamine the characteristics of patients in each IL28Bsubgroup. Study Design: Case-control study. Methods: IL28B polymorphisms were genotypedby Polymerase Chain Reaction and Restriction Frag- ment Length Polymorphism (PCR-RFLP) in all sub-jects. Results: The mean age was 52.3±10.9 years (33% fe- male) in the CHC patients and 52.5±11.5 years (39.1%female) in the healthy controls. The percentage of pa- tients with a high baseline viral load (≥400,000 IU/mL)was higher in the CT group (69.8%) compared to the C/C (44.4%) and T/T (50%) groups (p=0.021). Therewas no significant difference in liver fibrosis and livernecroinflammation distribution among the CC, CT andTT genotypes with mild, moderate and severe groups(p=0.058 and p=0.791, respectively). Mean age, gen-der ratio, body mass index, viral load at baseline, rateof HCV genotypes, baseline ALT levels were not sig-nificantly different among the three IL28B subgroups(p>0.05). A significant increase was observed in thefrequencies of IL28B rs12979860 TT genotypes in theCHC patients (20.6%) compared to the healthy controlgroup (8.7%) (p=0.033).Conclusion: In the patients with chronic HCV-genotype1b and 4 infections, the IL28B rs12979860 (C>T) genepolymorphism frequency of the TT genotype and T allelewas higher than in healthy control subjects. This resultindicates that the TT genotype may be more effective inthe progression of HCV infection than other genotypes.

🔖

Cite This Article

CANATAN, H., YILDIZ, O., KORKMAZ, K., TAHERİ, S., AYGEN, B., ZARARSIZ, G. (2022). Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal, Cilt: 32 - Sayı: 2, 147–155. https://ajindex.com/articles/461434

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Aygen B. Hepatitis C. Turkiye Klinikleri J Int Med Sci 2006;2:21- 33
  2. Aygen B. Kronik hepatit C’de tedavi ve izlem: In: Köksal İ, Leblebicioğlu H, editors. Kronik Hepatitlerin Tanı ve Te - davisinde Güncel Yaklaşımlar. 1st ed. Ankara: Bilimsel Tıp Yayınevi; 2009;223-33
  3. Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Hepatitis C and Occult Hepatitis C Infection among Hemodialysis Patients from Central Anatolia. J Pure Appl Microbiol 2014:8:435-40
  4. Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Frequency and epidemiologic characteristics of hepatitis C virus infection in patients receiving hemodialysis in our region. Klimik Journal 2012;25:19-23. [CrossRef] 5. Mıstık R, Türkiye’de viral hepatit epidemiyolojisi: yayınların irdelenmesi. In: Tabak F, Balik I, Tekeli E, editors. Viral Hepatit 2007. 1st ed. Ankara: Oban Matbaası; 2007;9-50
  5. Ökten A. Türkiye’de kronik hepatit, siroz ve hepatosellüler karsinoma etiyolojisi. Güncel Gastroenterol Derg 2003;7:187- 91
  6. Gökahmetoğlu S, Bozdayı M, Özbakır Ö, Aygen B, Özbal Y, Soyuer I, Yildiz O. Hepatitis C virus genotypes detected in Erci- yes University. J Turk Microbiol Soc 2007;37:35-8
  7. Gökahmetoğlu S, Atalay MA, Kılınç A. Determination of the hepatitis C virus genotypes with “pyrosequencing” method. Er - ciyes Med J 2011;33:99-102
  8. Aygen B, Yıldız O, Çaylan R, Köksal I, Saltoğlu N, Taşova Y, Leblebicioğlu H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C patients: results of a multicenter clinical trial. Viral Hepatitis Journal 2004;9:123-9
  9. Yıldız O, Aygen B, Alp E, Gökahmetoğlu S, Soyuer I. Retro - spective evaluation of different antiviral treatments for chronic hepatitis C infection. FLORA 2008;13:122-9
  10. Aygen, B, Yıldız O, Bostancı F, Özbakır Ö, Gökahmetoğlu S, Patıroğlu TE. A comparison of interferon-alpha-2b induction ther- apy with interferon-alpha-2b plus ribavirin combination therapy for the treatment of chronic hepatitis C. FLORA 2004;9:189-99
  11. Demiraslan H, Aygen B, Yıldız O, Soyuer I, Gökahmetoğlu S. A comparison of interferon α-2a plus ribavirin combination therapy with peginterferon α-2a plus ribavirin combination therapy for treat- ment of chronic hepatitis C. Viral Hepatitis Journal 2008;13:12-22
  12. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45. [